Paxlovid does not reduce long COVID risk in vaccinated individuals, study finds

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.

Senators question Chamber of Commerce’s motives around march-in rights

Sens. Elizabeth Warren (D-MA), Bernie Sanders (I-VT) and Jeff Merkley (D-OR) accused a new US Chamber of Commerce coalition of attempting to “stymie the White

May 11, 2024

Roche says its Carmot-acquired obesity pill is effective in early study

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 12, 2024

Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk,

January 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.